Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
Pope trip to Luxembourg, Belgium confirmed for September, 2 weeks after challenging Asia visit
Mainland welcomes more Taiwan young people to visit
HKSAR gov't welcomes policy of visa
China calls for strengthened flood control in Yangtze, Taihu Lake basins
Mohammad Mokhber: Who is Iran’s acting president?
Mali's historic city of Djenné mourns lack of visitors
East China's Jiangxi strives for high
Matt Waldron strikes out 10 as Padres silence Braves' bats in 3
Yvette Fielding says her Most Haunted co
Rays' Tyler Alexander comes within 5 outs of perfect game against Blue Jays
Kevin Pillar gets 1,000th career hit in Angels' win at Texas
Chinese police probe over 40,000 IPR infringement cases in 2023